- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00472251
One-year Prospective Observational Study of BMI Change Effect of 5-alpha Reductase Inhibitor in Korean BPH Patients
Aperçu de l'étude
Statut
Les conditions
Description détaillée
This study is a prospective, 1-year follow-up, observational study. We are planning to enroll 100 Korean patients with BPH. At each visit, patients' height, weight, abdominal circumference will be checked. Laboratory parameters including fasting glucose, HbA1c, serum testosterone, free testosterone, sex hormone-binding globulin, estradiol, maximum flow rate (measured by flowmetry) will be tested. Blood test will be performed twice (at baseline and at the end of study). 5mL of blood will be needed at each time from one subject. And total IPSS score will be evaluated after 1 year of treatment of 5 ARI. At every visit, use of above prohibited medicines and other medications will be investigated. In addition, any surgical procedures undertaken during study period will be asked and recorded.
Subjects of study will be allocated into 3 separate groups. Group 1 will be those taking 5 alpha reductase inhibitor (dutasteride) only for 1 year. Group2 will be those who switch from alpha blocker to dutasteride and take dutasteride for 1 year. Group 3 will be composed of those taking both alpha blocker and dutasteride for 1 year.
composed of
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
Kyunggi-do
-
Seongnam-si, Kyunggi-do, Corée, République de, 463-707
- Seoul National University Bundang Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Male patients with symptomatic BPH
- Prostate volume of 30 cm3 or greater measured by transrectal ultrasound
- International Prostatic Symptom Score(IPSS) of 9 or greater
- Maximum urinary flow rate (Qmax) of 15ml/s or less
- No definite evidence of prostate cancer (on transrectal ultrasound, DRE, or etc.)
- Given Informed consent
Exclusion Criteria:
- Post-void residual more than 250 mL
- History of cancer (including prostate cancer) or previous prostatic surgery
- Acute urinary retention within 3 months of enrollment
- Chronic alcohol abuser and heavy smoker (> 10 cigarettes/day)
- History of/current drug abuse including laxatives
- Any previous 5 ARI administration
- Type 1 DM or Type 2 DM regardless of treatment
- Clinically significant endocrine diseases at investigator's discretion including thyroid diseases.
- History of /current bulimia or anorexia nervosa
- Regular use of following prohibited medicines within 3 months prior to screening; A. Medicines which can affect salt/water retention such as diuretics, calcium channel blockers, gabapentin, pregabalin, etc B. Medicines which can affect body weight such as sibutramine, orlistat, phentermine, amphetamine, etc.
C. Anti-thyroid medication, thyroxine, cyproheptadine, tranquilizers, systemic corticosteroids, testosterone supplement, or other medications that are known to affect body weight or BMI
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
body mass index
Délai: after 1 year of treatment
|
after 1 year of treatment
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Sang Eun Lee, MD, PhD, Seoul National University Bundang Hospital
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CRT110446
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .